Pathfinder Cell Therapy Stock

Pathfinder Cell Therapy EBIT

The EBIT of Pathfinder Cell Therapy (PFND) as of Aug 16, 2026 is -1.12 M USD.

EBIT

-1.12 MUSD

Last updated:

In 2026, Pathfinder Cell Therapy's EBIT was -1.12 M USD, a % increase from the - USD EBIT recorded in the previous year.

The Pathfinder Cell Therapy EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2007
-5.35 base
Jan 1, 2008
-4.57 base
Jan 1, 2009
-4.12 base
Jan 1, 2010
-2.50 base
Jan 1, 2011
3.93 base
Jan 1, 2012
-2.06 base
Jan 1, 2013
-1.60 base
Jan 1, 2014
-1.12 base
YEAREBIT (M USD)
2014 -1.12
2013 -1.60
2012 -2.06
2011 3.93
2010 -2.50
2009 -4.12
2008 -4.57
2007 -5.35
2006 -4.54
2005 -2.46
2004 -2.38
2003 -2.02
2002 -1.28
2001 -1.08
2000 -1.04
1999 -2.26
1998 -7.76
1997 -8.22
1996 -4.37
1995 -2.98
Access this data via the Eulerpool API

Pathfinder Cell Therapy Revenue

Pathfinder Cell Therapy Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2007
134,000.00 USD
-5.35 M USD
-4.62 M USD
Jan 1, 2008
181,000.00 USD
-4.57 M USD
-4.40 M USD
Jan 1, 2009
360,000.00 USD
-4.12 M USD
-4.10 M USD
Jan 1, 2010
344,000.00 USD
-2.50 M USD
-2.08 M USD
Jan 1, 2011
73,000.00 USD
3.93 M USD
-18.92 M USD
Jan 1, 2012
114,000.00 USD
-2.06 M USD
-2.25 M USD
Jan 1, 2013
54,000.00 USD
-1.60 M USD
-1.81 M USD
Jan 1, 2014
0.00 USD
-1.12 M USD
-1.67 M USD

Pathfinder Cell Therapy Margins

Pathfinder Cell Therapy stock margins

The Pathfinder Cell Therapy margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pathfinder Cell Therapy. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pathfinder Cell Therapy.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2007
78.36 %
-3,988.81 %
-3,450.00 %
Jan 1, 2008
43.65 %
-2,527.07 %
-2,433.15 %
Jan 1, 2009
54.44 %
-1,144.44 %
-1,139.72 %
Jan 1, 2010
73.26 %
-726.45 %
-603.49 %
Jan 1, 2011
64.38 %
5,378.08 %
-25,920.55 %
Jan 1, 2012
56.14 %
-1,807.02 %
-1,975.44 %
Jan 1, 2013
31.48 %
-2,961.11 %
-3,353.70 %
Jan 1, 2014
31.48 %
- %
- %

Pathfinder Cell Therapy Stock analysis

What does Pathfinder Cell Therapy do? Pathfinder Cell Therapy Inc is a biopharmaceutical company specializing in the development of cell-based therapies. The company was founded in 2018 and is headquartered in Boston, Massachusetts. The founders of Pathfinder Cell Therapy have come together to develop innovative solutions for diseases that cannot be treated by conventional therapies. They believe that cell-based therapies have the potential to dramatically improve the lives of patients by directly addressing the underlying causes of their diseases. Pathfinder Cell Therapy's business model focuses on the development of cell-based therapies for specific diseases. The company works closely with academics, scientists, and clinicians to incorporate the latest knowledge and technologies into the development of new therapies. Pathfinder Cell Therapy has various divisions that focus on the development of cell-based therapies for specific diseases. One focus is on developing therapies for rare genetic diseases that are often difficult to treat. Other divisions focus on the development of therapies for cancer and autoimmune diseases. The company already has several products in development, including a cell-based therapy for the treatment of mucopolysaccharidosis type I (MPS-I), a rare genetic disease in which a specific type of sugar cannot be broken down and accumulates in various organs. Pathfinder Cell Therapy also plans to develop cell-based therapies for other rare genetic diseases such as Fabry disease and Krabbe disease. Another important product of Pathfinder Cell Therapy is a cell-based therapy for the treatment of certain types of cancer. This therapy harnesses the ability of immune cells to recognize and attack cancer cells to mobilize the body in the fight against cancer. This type of therapy is called immunotherapy and has made significant advances in recent years. Pathfinder Cell Therapy is also working on the development of cell-based therapies for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. In these diseases, the immune system mistakenly attacks healthy body cells. Cell-based therapies can help reprogram the immune system to only target pathogens and leave healthy cells unharmed. Overall, Pathfinder Cell Therapy aims to develop the next generation of cell-based therapies to treat diseases that have been difficult or impossible to treat in the past. The company has an experienced team of scientists who work closely with doctors and patients to ensure that their therapies can truly improve people's lives. Pathfinder Cell Therapy is still in the development phase, but the company has already made promising progress and is expected to achieve further success in the coming years. Pathfinder Cell Therapy is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Pathfinder Cell Therapy's EBIT

Pathfinder Cell Therapy's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Pathfinder Cell Therapy's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Pathfinder Cell Therapy's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Pathfinder Cell Therapy’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Pathfinder Cell Therapy stock

EBIT of Pathfinder Cell Therapy is -1.12 M USD in 2026.

On Eulerpool you can find the complete historical development of EBIT Pathfinder Cell Therapy since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Pathfinder Cell Therapy historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Pathfinder Cell Therapy

All Key Metrics — Pathfinder Cell Therapy